News & Updates

Among patients with chronic hepatitis B (CHB), treatment with entecavir (ETV) and Biejia-Ruangan compound (BRC), an antifibrotic traditional Chinese medicine, helps reduce the risk of hepatocellular carcinoma (HCC), a recent study reports.

Among patients with nonalcoholic fatty liver disease (NAFLD), eradication treatment against Helicobacter pylori may help improve liver steatosis and metabolic parameters, a recent study has found.

Using liver stiffness measurements (LSM) combined with routine clinical parameters, Agile 3+, and Agile 4, both noninvasive scoring methods, can accurately identify advanced fibrosis (AF) and cirrhosis, respectively, in patients with nonalcoholic fatty liver disease (NAFLD), reports a new study.

Patients with severe obesity and nonalcoholic fatty liver disease (NAFLD) appear to benefit from bariatric surgery, which significantly reduces the risk of cardiovascular disease (CVD), a study has found.

High glycaemic burden is associated with hepatocellular carcinoma (HCC) development and fibrosis progression in patients with chronic hepatitis B (CHB) and type 2 diabetes (T2D) (CHB + T2D), researchers from the University of Hong Kong (HKU) have reported.

Patients with biopsy-proven alcohol-related liver disease (ALD) appear to have a higher frequency of cardiovascular disease (CVD) than their counterparts without ALD, according to a study. The increased rates are especially pronounced just after ALD diagnosis.

A third-dose administration of a COVID-19 mRNA vaccine results in a more substantial decrease in COVID-19 in patients with cirrhosis compared with the general population, according to a study. This suggests that the third dose can overcome vaccine hyporesponsiveness in this population.

A 23-year longitudinal follow-up in a population-based cohort has shown a slowly progressive trend in nonalcoholic fatty liver disease (NAFLD), with liver-related outcomes affecting only a small number of people, reports a recent study.